Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Markets
  • Movers
  • Pre-Market Outlook

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights
Today, 7:13 AM
 

ACOR

Read More
3 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

22 Stocks Moving in Thursday’s Pre-Market Session

By Lisa Levin
Today, 7:13 AM
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business combination.

ADSK

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $185

By vishwanath@benzinga.com
Today, 7:13 AM
Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $178 to $185.

ASND

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $182

By Benzinga Newsdesk
Today, 7:13 AM
SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $178 to $182.

ASND

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights
Today, 7:13 AM
Gainers

ADVM

Read More
9 minute read
  • FDA
  • News

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

By Michael Horton
Today, 7:13 AM
SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –   - Once weekly

ASND

Read More
4 minute read
  • Biotech
  • Earnings
  • FDA
  • General
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug

By Shanthi Rexaline
Today, 7:13 AM
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24)

AGEN

Read More
3 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For August 25, 2021

By Benzinga Insights
Today, 7:13 AM
  Companies Reporting Before The Bell • Jiayin Gr (NASDAQ:JFIN) is projected to report quarterly earnings at $0.21 per share on revenue of $54.80 million.

ADSK

Read More
2 minute read
  • Biotech
  • Earnings
  • FDA
  • News
  • Penny Stocks
  • Previews
  • Small Cap
  • Top Stories
  • Trading Ideas

The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More

By Shanthi Rexaline
Today, 7:13 AM
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues, clinical readouts and regulatory actions that moved stocks during the week.

ABVC

Read More
1 minute read
  • Media
  • Trading Ideas

Hookipa Shares Move Higher Following Circulation Of TipRanks Article ‘3 “Strong Buy” Stocks Trading at Rock-Bottom Prices’; BioXcel, Ascendis Shares Also Mentioned

By Benzinga Newsdesk
Today, 7:13 AM
https://www.tipranks.com/news/article/3-strong-buy-stocks-trading-at-rock-bottom-prices-2

ASND

Posts navigation

Previous 1 … 6 7 8 9 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service